- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
9 result(s) found for: Filler.
Displaying page 1 of 1.
EudraCT Number: 2019-001151-40 | Sponsor Protocol Number: CTU148N | Start Date*: 2019-07-09 |
Sponsor Name:RIEMSER Pharma GmbH | ||
Full Title: Phase II pilot study: To determine an effective and tolerable dose of Hylase® "Dessau" (bovine hyaluronidase) in the treatment of hyaluronic acid filler overshoots by injection into defined areas o... | ||
Medical condition: In this study, healthy subjects get an artificial over-injection with Hyaluron acid filler on the back of the hands. To demonstrate the effectiveness of hylase® "Dessau" as an antidote for hyaluro... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-001203-50 | Sponsor Protocol Number: 05DF1211 | Start Date*: 2014-07-31 |
Sponsor Name:Q-med AB | ||
Full Title: An evaluator-blinded multi-center study of combined treatment with Azzalure, Restylane/Emervel filler and Restylane skinbooster as compared to single treatment with either Azzalure alone or Restyla... | ||
Medical condition: Subjects with the intention to undergo facial aesthetic treatment and who are likely to benefit from a combination of injection treatments | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001202-17 | Sponsor Protocol Number: 05PDF1401 | Start Date*: 2014-07-31 |
Sponsor Name:Q-med AB | ||
Full Title: An evaluator-blinded multi-center study of combined treatment with Azzalure/Dysport, Restylane/Emervel filler and Restylane skinbooster as compared to single treatment with either Azzalure/Dysport ... | ||
Medical condition: Subjects with the intention to undergo facial aesthetic treatment and who are likely to benefit from a combination of injection treatments | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020057-13 | Sponsor Protocol Number: 034-002 | Start Date*: 2010-06-11 | |||||||||||
Sponsor Name:Dermatologikum Hamburg | |||||||||||||
Full Title: Proof-of-concept-study to Evaluate the Efficacy and Tolerability of Repeated Versus Single Treatment with Botulinum-Toxin (Vistabel®) Treatment in Combination with a Hyaluronic Acid (Juvederm-Ultra... | |||||||||||||
Medical condition: moderate to severe glabellar frown lines | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023006-12 | Sponsor Protocol Number: 2010-362 | Start Date*: 2011-01-14 | |||||||||||
Sponsor Name:Professor Krzysztof Tadeusz Drzewiecki | |||||||||||||
Full Title: Lipofilling with MSC enriched fat, a permanent autologous filler? | |||||||||||||
Medical condition: Patients who have a need of reconstruction after surgery, eg. after mastectomy. The purpose of this clinical trial, is to make a reproducible and safe method for fat transplantation, that can be us... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004779-36 | Sponsor Protocol Number: BMTI-2006-03-EU | Start Date*: 2007-01-22 | |||||||||||
Sponsor Name:BioMimetic Therapeutic Inc | |||||||||||||
Full Title: A Human Clinical Trial to Evaluate the Safety and Clinical Utility of GEM OS1 as a Bone Regeneration System in Foot and Ankle Arthrodesis Procedures | |||||||||||||
Medical condition: For use as a bone void filler for voids or gaps that are not intrinsic to the stability of bony structure. Treatment of surgically created osseous defects or osseous defects resulting from patholo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012436-32 | Sponsor Protocol Number: IVIST01 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Medizinische Hochschule Hannover | |||||||||||||
Full Title: A multicenter, randomized, open-labeled study to steer immunsuppressive and antiviral therapy by measurement of virus- (CMV, ADV, HSV) specific T cells in addition to determination of trough levels... | |||||||||||||
Medical condition: After solid organ transplantation immunosuppressive treatment disrupts the individual balance between virus-replication and cellular immune response. This can lead to an elevated risk of severe vir... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002986-11 | Sponsor Protocol Number: CAEB071A2203E1 | Start Date*: 2007-09-05 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A 24 month extension to a 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic® after 3 months), vs.... | ||
Medical condition: The study is a continuation of a CNI-sparing study in which 2/3rds of patients were converted to a non CNI regimen after 3 months (core study). The others remained on a CNI Control arm. The extensi... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) GB (Prematurely Ended) DE (Prematurely Ended) IT (Completed) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-003494-25 | Sponsor Protocol Number: CAEB071A2203 | Start Date*: 2006-08-30 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. myfortic plus tacrolimus i... | ||
Medical condition: First evaluation of the efficacy and safety of AEB071 in its target indication: prevention of rejection in solid organ tranplantation. The study population will consist of a representative group of... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
